2026-06-23

Silver volume spike - 616.9× the 20-day average (58,216 vs 94 avg)

Copper volume spike - 49.0× the 20-day average (53,037 vs 1,081 avg)

Platinum volume spike - 1475.6× the 20-day average (18,562 vs 12 avg)

Gold volume spike - 18.4× the 20-day average (115,842 vs 6,311 avg)

Corn bull 6.4% vs prior close ($411.50 → $437.75)

OSINT: US Air Force Deploys 9 Refueling Aircraft Over Strait of Hormuz

OSINT: Trump says Strait of Hormuz will stay open, 19M barrels flow record

CFTC COPPER speculators at extreme long: 52-week positioning extreme

OSINT: Russian stocks dip at open on June 23

OSINT: Russian waste-processing investments plunge sixfold to 12.6 bn rubles

OSINT: Ukrainian drones strike Russian missile depot in Crimea, trigger big blast

Oil -2.41%: significant decline on the session

Silver bear 5.9% vs prior close ($65.53 → $61.63)

RBOB Gasoline bear 4.8% vs prior close ($2.99 → $2.84)

Cotton bull 4.4% vs prior close ($75.21 → $78.50)

Sugar No. 11 bull 4.3% vs prior close ($13.35 → $13.93)

OSINT: US Senate backs bill to halt US military action against Iran

Gold -1.01%: significant decline on the session

Oil -2.41%: significant decline on the session

ETH ETF outflow of $190M - institutional selling

BTC ETF outflow of $2218M - institutional selling

SOL open interest -32.5% - OI collapse

ETH open interest -68.8% - OI collapse

BTC open interest +60.2% - OI surge

BITCOIN - speculators net long (+2.5σ vs 52w mean) - contrarian bear signal

SOL open interest -58.8% - OI collapse

BTC open interest +94.6% - OI surge

ETH open interest -66.4% - OI collapse

BTC open interest +100.5% - OI surge

SOL open interest +39.2% - OI surge

ETH open interest -68.2% - OI collapse

SOL open interest +39.3% - OI surge

ETH open interest -67.7% - OI collapse

BTC open interest -40.7% - OI collapse

OSINT: Nvidia market cap slips below $5 trillion as shares tumble 4%

OSINT: Fed December Rate Hike Odds Surge to 77%

SOL DEX volume/liquidity ratio elevated (0.89x): on-chain trade volume 0.89x liquidity

OSINT: Oobit Links USDT to Brazil’s Pix, Unlocking Crypto Payments for 170M Users

OSINT: US Treasury sanctions 9 individuals, 26 entities in SE Asian crypto fraud scheme

OSINT: US Senate bans Fed CBDC until 2030, protects private stablecoins

Phase 3 trial terminated early - JOHNSON A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Mo

Phase 3 trial terminated early - JOHNSON A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80

Phase 3 trial terminated early - JOHNSON A Study of the Effectiveness and Safety of Tramadol HCl/Acetaminophen Compared t

Phase 3 trial terminated early - ELI An Open Label Study for Participants With Rheumatoid Arthritis

Phase 3 trial terminated early - ELI A Long-Term, Open-Label, Study on Schizophrenia

Phase 3 trial terminated early - ELI ERCC1 Targeted Trial

Phase 3 trial terminated early - BRISTOL FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocar

Phase 3 trial terminated early - BIOGEN Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Phase 3 trial terminated early - AMGEN Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperpara

Phase 3 trial terminated early - AMGEN Denosumab in Primary Hyperparathyroidism

Phase 3 trial terminated early - AMGEN Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatri

Phase 3 trial terminated early - INCYTE Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Dou

Phase 3 trial terminated early - Medtronic EnTRINSIC - EnPulse Trial on Search AV+ Influence

Phase 3 trial terminated early - Medtronic Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy

Phase 3 trial terminated early - Merck Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodrom

Phase 3 trial terminated early - PFIZER Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthr

Phase 3 trial terminated early - PFIZER Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

Phase 3 trial terminated early - PFIZER Tanezumab In Osteoarthritis Of The Hip Or Knee

Phase 3 trial terminated early - PFIZER Dextromethorphan Pediatric Acute Cough Study

Phase 3 trial terminated early - ABBOTT Evaluation of Resynchronization Therapy for Heart Failure

Phase 3 trial terminated early - GILEAD Study of Obeldesivir in Children and Adolescents With COVID-19

HARTFORD INSURANCE GROUP, INC. search volume spiked +100 pts - unusual interest

OSINT: US Tech Momentum ETF Soars 38% YTD, Outpacing S&P 500

Callaway Golf Co search volume spiked +100 pts - unusual interest

SHOPIFY INC. search volume spiked +60 pts - unusual interest

CITIGROUP INC search volume spiked +100 pts - unusual interest

OSINT: Nvidia market cap slips below $5 trillion as shares tumble 4%

EXELON CORP search volume spiked +100 pts - unusual interest

OSINT: Fed December Rate Hike Odds Surge to 77%

OSINT: South Korea's KOSPI plunges 9.99% - largest one‑day fall in history

GAP INC search volume spiked +57 pts - unusual interest

OSINT: Oobit Links USDT to Brazil’s Pix, Unlocking Crypto Payments for 170M Users

HARTFORD INSURANCE GROUP, INC. search volume spiked +100 pts - unusual interest

SHOPIFY INC. search volume spiked +60 pts - unusual interest

CITIGROUP INC search volume spiked +100 pts - unusual interest

Q2-2025: Missed consensus by 16.7% - EPS $-1.25 vs $-1.071 estimate

Q4-2025: Missed consensus by 96.1% - EPS $-0.1 vs $-0.051 estimate

Q1-2026: Beat consensus by 20.5% - EPS $2.56 vs $2.124 estimate

Q1-2026: Beat consensus by 14.2% - EPS $-0.35 vs $-0.408 estimate

Q3-2025: Beat consensus by 30.0% - EPS $1.05 vs $0.808 estimate

Q1-2026: Beat consensus by 37.2% - EPS $2.72 vs $1.983 estimate

Q1-2025: Beat consensus by 31.4% - EPS $-0.07 vs $-0.102 estimate

Q3-2025: Beat consensus by 58.0% - EPS $-0.03 vs $-0.0714 estimate

Q1-2026: Missed consensus by 65.6% - EPS $2.22 vs $6.4582 estimate

Q3-2025: Beat consensus by 49.0% - EPS $-0.13 vs $-0.255 estimate

Q4-2025: Beat consensus by 359.8% - EPS $0.53 vs $-0.204 estimate

Q1-2026: Beat consensus by 14.3% - EPS $3.45 vs $3.0175 estimate

Q4-2025: Missed consensus by 12.9% - EPS $0.16 vs $0.1836 estimate

Q2-2025: Beat consensus by 19.8% - EPS $0.22 vs $0.1836 estimate

Q4-2025: Beat consensus by 251.2% - EPS $1.97 vs $0.561 estimate

Q2-2026: Missed consensus by 5.6% - EPS $0.54 vs $0.572 estimate

Q3-2025: Beat consensus by 5.2% - EPS $4.73 vs $4.497 estimate

Q4-2025: Missed consensus by 78.7% - EPS $0.43 vs $2.016 estimate

Q1-2026: Beat consensus by 6.7% - EPS $1.44 vs $1.3498 estimate

Q1-2022: Missed consensus by 70.3% - EPS $-66 vs $-38.76 estimate

Q4-2021: Missed consensus by 1811.8% - EPS $-78 vs $-4.08 estimate

Q1-2011: Missed consensus by 14.4% - EPS $-1.4 vs $-1.224 estimate

Q2-2011: Missed consensus by 26.1% - EPS $-2.1 vs $-1.666 estimate

Q4-2011: Beat consensus by 117.9% - EPS $2 vs $0.918 estimate

Q3-2011: Missed consensus by 88.2% - EPS $0.9 vs $7.65 estimate

Q4-2025: Missed consensus by 2384.8% - EPS $-40.95 vs $-1.648 estimate

Q2-2025: Missed consensus by 9.8% - EPS $0.65 vs $0.721 estimate

Q4-2025: Beat consensus by 46.5% - EPS $-0.3 vs $-0.561 estimate

Q3-2025: Missed consensus by 27.5% - EPS $-0.52 vs $-0.408 estimate

Q1-2026: Beat consensus by 55.5% - EPS $-0.11 vs $-0.247 estimate

Q1-2025: Beat consensus by 116.8% - EPS $36 vs $-214.2 estimate

Q3-2024: Beat consensus by 12.7% - EPS $46 vs $40.8 estimate

Q2-2024: Beat consensus by 222.5% - EPS $100 vs $-81.6 estimate

Q4-2024: Beat consensus by 173.0% - EPS $32 vs $-43.86 estimate

Q1-2026: Missed consensus by 25.2% - EPS $-0.81 vs $-0.647 estimate

Q4-2023: Missed consensus by 334.6% - EPS $-232.75 vs $-53.55 estimate

Q4-2025: Beat consensus by 117.9% - EPS $0.2 vs $0.0918 estimate

Q3-2025: Beat consensus by 33.1% - EPS $0.37 vs $0.278 estimate

Q3-2001: Beat consensus by 23.0% - EPS $0.06519 vs $0.053 estimate

Q1-2026: Missed consensus by 131.0% - EPS $-2.71 vs $-1.173 estimate

Q3-2025: Missed consensus by 26.5% - EPS $0.45 vs $0.612 estimate

Q1-2026: Beat consensus by 22.7% - EPS $-6.58 vs $-8.517 estimate

Q4-2025: Missed consensus by 21.6% - EPS $0.08 vs $0.102 estimate

Q3-2025: Beat consensus by 21.0% - EPS $11.83 vs $9.78 estimate

Q3-1995: Missed consensus by 128.8% - EPS $-168 vs $-73.44 estimate

Q1-1996: Missed consensus by 458.8% - EPS $-228 vs $-40.8 estimate

Q4-1998: Missed consensus by 55.4% - EPS $20 vs $44.88 estimate

Q1-2026: Missed consensus by 56.9% - EPS $-0.08 vs $-0.051 estimate

Q4-2025: Beat consensus by 5.6% - EPS $0.34 vs $0.322 estimate

Q4-2018: Missed consensus by 67.3% - EPS $0.1 vs $0.306 estimate

Q4-2025: Beat consensus by 9.1% - EPS $1.13 vs $1.0353 estimate

Q1-2026: Beat consensus by 7.5% - EPS $1.01 vs $0.9399 estimate

Q2-2025: Missed consensus by 24.3% - EPS $-0.26 vs $-0.2091 estimate

Q4-2025: Missed consensus by 56.9% - EPS $-0.16 vs $-0.102 estimate

Q3-2025: Beat consensus by 5.7% - EPS $1.13 vs $1.069 estimate

Missed consensus by 313.4% - EPS $-1 vs $-0.2419 estimate

Q4-2025: Beat consensus by 29.7% - EPS $-0.45 vs $-0.64 estimate

Q3-2025: Missed consensus by 96.1% - EPS $-0.14 vs $-0.0714 estimate

Q2-2025: Beat consensus by 639.2% - EPS $0.55 vs $-0.102 estimate

Q2-2025: Beat consensus by 30.1% - EPS $-0.52 vs $-0.744 estimate

Q4-2025: Beat consensus by 7.7% - EPS $-0.82 vs $-0.888 estimate

Q3-2025: Missed consensus by 20.0% - EPS $-1.03 vs $-0.858 estimate

Q1-2026: Missed consensus by 17.6% - EPS $1.48 vs $1.7967 estimate

Q3-2025: Beat consensus by 33.8% - EPS $-0.1 vs $-0.151 estimate

Q4-2025: Beat consensus by 6.7% - EPS $0.19 vs $0.178 estimate

Q2-2025: Missed consensus by 14.5% - EPS $-0.26 vs $-0.227 estimate

Q2-2025: Beat consensus by 5.1% - EPS $4.24 vs $4.033 estimate

Q4-2024: Missed consensus by 28.2% - EPS $20.22 vs $28.179 estimate

Q3-2026: Missed consensus by 1139.6% - EPS $-2.1 vs $0.202 estimate

Q4-2022: Missed consensus by 151.2% - EPS $-1575 vs $3079.125 estimate

Q3-2022: Missed consensus by 134.5% - EPS $-831.25 vs $2409.75 estimate

Q2-2025: Beat consensus by 17.6% - EPS $-0.504 vs $-0.612 estimate

Q3-2025: Missed consensus by 10.7% - EPS $0.35 vs $0.392 estimate

Q4-2025: Beat consensus by 18.0% - EPS $0.44 vs $0.373 estimate

Q2-2026: Missed consensus by 35.4% - EPS $0.34 vs $0.526 estimate

Q3-2026: Missed consensus by 236.8% - EPS $-0.78 vs $0.57 estimate

Q2-2026: Missed consensus by 17.6% - EPS $1.96 vs $2.38 estimate

Q4-2025: Missed consensus by 24.3% - EPS $0.53 vs $0.7 estimate

Q2-2025: Beat consensus by 41.0% - EPS $0.53 vs $0.376 estimate

Q2-2025: Beat consensus by 46.2% - EPS $22.54 vs $15.414 estimate

Q4-2025: Missed consensus by 24.7% - EPS $0.064 vs $0.085 estimate

Q3-2025: Missed consensus by 14.4% - EPS $-0.07 vs $-0.0612 estimate

Q3-2023: Missed consensus by 7.7% - EPS $-70 vs $-65.025 estimate

Q4-2024: Missed consensus by 365.1% - EPS $-37.95 vs $-8.16 estimate

Q3-2024: Beat consensus by 69.8% - EPS $-2 vs $-6.63 estimate

Q4-2023: Beat consensus by 36.6% - EPS $-43 vs $-67.83 estimate

Q2-2023: Missed consensus by 104.8% - EPS $-0.94 vs $-0.459 estimate

Q1-2024: Missed consensus by 57.1% - EPS $-159 vs $-101.235 estimate

Q4-2008: Missed consensus by 98.0% - EPS $-20 vs $-10.1 estimate

Q3-2008: Missed consensus by 890.1% - EPS $-50 vs $-5.05 estimate

Q1-2009: Missed consensus by 395.0% - EPS $-25 vs $-5.05 estimate

Q1-2026: Beat consensus by 137.6% - EPS $0.027 vs $-0.0719 estimate

Q4-2025: Beat consensus by 145.1% - EPS $0.5 vs $0.204 estimate

Q1-2026: Missed consensus by 472.5% - EPS $-0.19 vs $0.051 estimate

Q4-2025: Missed consensus by 28.3% - EPS $0.39 vs $0.544 estimate

Q1-2025: Beat consensus by 31.6% - EPS $1.87 vs $1.4214 estimate

Q4-2025: Beat consensus by 17.0% - EPS $0.46 vs $0.393 estimate

Q1-2027: Missed consensus by 181.9% - EPS $-0.46 vs $-0.1632 estimate

Q1-2026: Beat consensus by 6.3% - EPS $7.34 vs $6.903 estimate

Q4-2025: Beat consensus by 207.1% - EPS $1.42 vs $-1.326 estimate

Q2-2025: Beat consensus by 29.5% - EPS $-12.3 vs $-17.442 estimate

Q4-2023: Missed consensus by 272.5% - EPS $-9.5 vs $-2.55 estimate

Q4-2025: Missed consensus by 8.3% - EPS $1.04 vs $1.134 estimate

Q3-2025: Missed consensus by 5.7% - EPS $1.03884 vs $1.102 estimate

Q2-2025: Missed consensus by 41.2% - EPS $-0.16 vs $-0.1133 estimate

Q3-2025: Missed consensus by 23.5% - EPS $0.138 vs $0.1803 estimate

Q4-2025: Beat consensus by 79.9% - EPS $0.125 vs $0.0695 estimate

Q1-2026: Beat consensus by 9.6% - EPS $0.096 vs $0.0876 estimate

Q3-2011: Beat consensus by 6.1% - EPS $3 vs $2.828 estimate

Q1-2026: Missed consensus by 10.1% - EPS $40.1 vs $44.603 estimate

Q4-2025: Missed consensus by 152.1% - EPS $-0.05 vs $0.096 estimate

EXELON CORP search volume spiked +100 pts - unusual interest

Q2-2025: Beat consensus by 79.7% - EPS $0.55 vs $0.306 estimate

china_us_west shipping +13.3% - potential inflation signal

china_us_west shipping +13.3% - potential inflation signal

OSINT: Ukrainian drones strike Russian missile depot in Crimea, trigger big blast

OSINT: US Senate backs bill to halt US military action against Iran

VIX at 19.5: CAUTION territory

OSINT: Ukrainian drones strike Russian missile depot in Crimea, trigger big blast

DXY +0.37% - dollar strength signal

OSINT: Fed December Rate Hike Odds Surge to 77%

OSINT: US Senate backs bill to halt US military action against Iran

OSINT: South Korea's KOSPI plunges 9.99% - largest one‑day fall in history

OSINT: Oobit Links USDT to Brazil’s Pix, Unlocking Crypto Payments for 170M Users

OSINT: US Senate bans Fed CBDC until 2030, protects private stablecoins